Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AESOP: Obeticholic Acid in Primary Sclerosing Cholangitis
NCT02177136Phase 2Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Feb 2015
- Primary completion
- Mar 2017
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of obeticholic acid in Primary Sclerosing Cholangitis (PSC), sponsored by Intercept Pharmaceuticals. Started Feb 2015; status: completed.
02
Drugs
obeticholic acid
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT02177136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02177136.